MagForce AG (MF6) - Net Assets

Latest as of December 2021: €26.84 Million EUR ≈ $31.38 Million USD

Based on the latest financial reports, MagForce AG (MF6) has net assets worth €26.84 Million EUR (≈ $31.38 Million USD) as of December 2021. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€62.83 Million ≈ $73.45 Million USD) and total liabilities (€35.99 Million ≈ $42.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read MF6 total liabilities for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric Value
Current Net Assets €26.84 Million
% of Total Assets 42.72%
Annual Growth Rate 13.91%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 76.95

MagForce AG - Net Assets Trend (2018–2021)

This chart illustrates how MagForce AG's net assets have evolved over time, based on quarterly financial data. Also explore MF6 asset base for the complete picture of this company's asset base.

Annual Net Assets for MagForce AG (2018–2021)

The table below shows the annual net assets of MagForce AG from 2018 to 2021. For live valuation and market cap data, see how much is MagForce AG worth.

Year Net Assets Change
2021-12-31 €26.84 Million
≈ $31.38 Million
-24.42%
2020-12-31 €35.51 Million
≈ $41.52 Million
+141.46%
2019-12-31 €14.71 Million
≈ $17.20 Million
-19.00%
2018-12-31 €18.16 Million
≈ $21.23 Million
--

Equity Component Analysis

This analysis shows how different components contribute to MagForce AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 455820800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2021)

Component Amount Percentage
Common Stock €29.93 Million 111.52%
Other Components €53.53 Million 199.44%
Total Equity €26.84 Million 100.00%

MagForce AG Competitors by Market Cap

The table below lists competitors of MagForce AG ranked by their market capitalization.

Company Market Cap
SCANDION ONC. DK-0735
F:8VY
$140.86K
QuiaPEG Pharmaceuticals Holding AB
ST:QUIA
$141.00K
Sotherly Hotels Inc Series B Pref
NASDAQ:SOHOB
$141.67K
EVRAZ plc
LSE:EVR
$143.76K
Akoustis Technologies, Inc.
NASDAQ:AKTSQ
$138.60K
DSW Capital PLC
LSE:DSW
$137.60K
Mosman Oil and Gas Ltd
LSE:MSMN
$136.82K
Block Energy PLC
LSE:BLOE
$135.95K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in MagForce AG's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2020 to 2021, total equity changed from 35,514,720 to 26,840,455, a change of -8,674,264 (-24.4%).
  • Net loss of 10,574,258 reduced equity.
  • Other factors increased equity by 1,899,994.

Equity Change Factors (2020 to 2021)

Factor Impact Contribution
Net Income €-10.57 Million -39.4%
Other Changes €1.90 Million +7.08%
Total Change €- -24.42%

Book Value vs Market Value Analysis

This analysis compares MagForce AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.00x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2018-12-31 €0.69 €0.00 x
2019-12-31 €0.53 €0.00 x
2020-12-31 €1.21 €0.00 x
2021-12-31 €0.90 €0.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently MagForce AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -39.40%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -3004.19%
  • • Asset Turnover: 0.01x
  • • Equity Multiplier: 2.34x
  • Recent ROE (-39.40%) is below the historical average (-8.31%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2018 24.00% 6485.20% 0.00x 2.04x €2.54 Million
2019 -59.36% -1039.44% 0.02x 2.49x €-10.20 Million
2020 41.52% 2374.12% 0.01x 1.85x €11.20 Million
2021 -39.40% -3004.19% 0.01x 2.34x €-13.26 Million

Industry Comparison

This section compares MagForce AG's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $934,837,026
  • Average return on equity (ROE) among peers: -23.67%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
MagForce AG (MF6) €26.84 Million 24.00% 1.34x $139.97K
HeraMED Limited (1I4) $2.59 Million -168.10% 0.60x $26.40 Million
Medtronic PLC (2M6) $841.50 Million 23.43% 0.53x $102.18 Billion
Peijia Medical Limited (4WO) $2.04 Billion -11.08% 0.32x $403.65 Million
AVITA Medical Inc (51KB) $20.86 Million -118.03% 0.23x $172.49 Million
MICROPORT CARDIO.MEDTECH. (72X) $2.22 Billion -2.23% 0.20x $107.57 Million
MODULIGHT OY EO 1 (78W) $44.68 Million -10.30% 0.10x $43.97 Million
ACOTEC SCIEN.H. DL-00001 (7W3) $1.28 Billion 5.50% 0.11x $377.38 Million
LIFETECH SCI.DL-00000125 (81X) $2.53 Billion 11.56% 0.26x $893.41 Million
ORTOMA AB B (82Y) $142.72 Million -13.45% 0.13x $26.39 Million
COPLAND ROAD CAPITAL NEW (A2P) $223.54 Million 46.04% 1.19x $594.67 Million

About MagForce AG

STU:MF6 Germany Medical Devices
Market Cap
$139.97K
€119.73K EUR
Market Cap Rank
#30898 Global
#2781 in Germany
Share Price
€0.00
Change (1 day)
-11.11%
52-Week Range
€0.00 - €0.01
All Time High
€8.80
About

MagForce AG develops advanced nanomedicine for cancer therapies. It offers NanoTherm therapy system, a combination of medical devices for the treatment of solid brain tumors; NanoPlan, a software that stimulates the temperature distribution in the treatment area; NanoTherm, a magnetic ferrofluid; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered i… Read more